OverviewSuggest Edit

Bristol-Myers Squibb is a biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with serious and life-threatening diseases. Its medicines help patients in disease areas such as oncology, cardiovascular, immunoscience, fibrosis, and others.
TypePublic
Founded1887
HQNew York, NY, US
Websitebms.com
Employee Ratings4.1
Overall CultureA

Latest Updates

Employees (est.) (Dec 2019)30,000(+29%)
Job Openings2,557
Revenue (FY, 2020)$42.5 B(+63%)
Share Price (Jun 2021)$67.3
Cybersecurity ratingBMore

Key People/Management at Bristol-Myers Squibb

Giovanni Caforio

Giovanni Caforio

Chairman of the Board and Chief Executive Officer
Jeff Staiger

Jeff Staiger

Vice President, Cardiovascular, Fibrosis, Immunology, Neuroscience Business Development
Elizabeth Mily

Elizabeth Mily

Executive Vice President Strategy and Business Development
Rupert Vessey

Rupert Vessey

Executive Vice President and President, Research and Early Development
Brian Heaphy

Brian Heaphy

Vice President, Corporate Development
Sandra Leung

Sandra Leung

Executive Vice President, General Counsel
Show more

Bristol-Myers Squibb Office Locations

Bristol-Myers Squibb has offices in New York, Atlanta, Baltimore, Cambridge and in 50 other locations
New York, NY, US (HQ)
345 Park Avenue, 345 Park Ave
Atlanta, GA, US
950 East Paces Ferry Rd NE
Baltimore, MD, US
Baltimore, MD, USA
Cambridge, MA, US
100 Binney St
Columbus, OH, US
999 Polaris Pkwy #100
Devens, MA, US
38 Jackson Rd
Show all (56)

Bristol-Myers Squibb Financials and Metrics

Bristol-Myers Squibb Revenue

Embed Graph
View revenue for all periods
Bristol-Myers Squibb's revenue was reported to be $42.52 b in FY, 2020
USD

Revenue (Q1, 2021)

11.1b

Gross profit (Q1, 2021)

8.2b

Gross profit margin (Q1, 2021), %

74.3%

Net income (Q1, 2021)

2.0b

Market capitalization (11-Jun-2021)

150.4b

Closing stock price (11-Jun-2021)

67.3

Cash (31-Mar-2021)

11.0b

EV

185.7b
Bristol-Myers Squibb's current market capitalization is $150.4 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

20.8b22.6b26.1b42.5b

Revenue growth, %

7%9%16%

Cost of goods sold

6.1b6.5b8.1b11.8b

Gross profit

14.7b16.0b18.1b30.7b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

5.2b5.7b5.7b5.9b6.3b6.0b10.8b10.1b10.5b11.1b

Cost of goods sold

1.6b1.6b1.6b1.8b2.0b1.8b3.7b2.7b2.5b2.8b

Gross profit

3.6b4.1b4.0b4.1b4.3b4.2b7.1b7.4b8.0b8.2b

Gross profit Margin, %

69%72%71%69%68%70%66%73%76%74%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

5.4b6.9b12.3b14.5b

Accounts Receivable

6.3b6.0b7.7b8.5b

Prepaid Expenses

576.0m

Inventories

1.2b1.2b4.3b2.1b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

5.3b5.0b5.4b7.3b28.4b30.5b15.8b19.9b19.4b11.0b

Accounts Receivable

5.7b5.6b5.9b5.7b5.7b5.5b8.3b7.9b8.1b8.7b

Prepaid Expenses

965.0m998.0m886.0m

Inventories

1.2b1.2b1.3b1.3b1.3b1.2b2.8b2.4b1.9b2.0b
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

975.0m4.9b3.5b(9.0b)

Depreciation and Amortization

789.0m637.0m1.7b10.4b

Inventories

(29.0m)(216.0m)463.0m2.7b

Accounts Payable

320.0m(59.0m)229.0m188.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

1.5b1.9b3.8b1.7b3.2b4.5b(766.0m)(846.0m)1.0b2.0b

Depreciation and Amortization

143.0m300.0m465.0m223.0m443.0m510.0m2.6b5.0b7.7b2.7b

Inventories

(4.0m)(122.0m)(152.0m)35.0m28.0m(7.0m)1.4b2.1b2.6b106.0m

Accounts Payable

(241.0m)(101.0m)(186.0m)136.0m156.0m48.0m703.0m480.0m56.0m303.0m
USDFY, 2017

Revenue/Employee

876.6k

Debt/Equity

0.7 x

Debt/Assets

0.2 x

Financial Leverage

2.8 x
Show all financial metrics

Bristol-Myers Squibb Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Manufacturing Facilities

677

Phase I Trials Products (Hematology)

14

Projects in R&D Pipeline

3244

Research and Development Centers

7712
Show all operating metrics

Bristol-Myers Squibb Acquisitions / Subsidiaries

Company NameDateDeal Size
MyoKardiaOctober 05, 2020$13.1 b
ForbiusAugust 24, 2020
CelgeneJanuary 03, 2019$74 b
IFM TherapeuticsAugust 03, 2017
Cormorant PharmaceuticalsJuly 05, 2016
Padlock TherapeuticsMarch 23, 2016$600 m
Cardioxyl PharmaceuticalsNovember 02, 2015$2 b
Flexus BiosciencesFebruary 23, 2015$1.25 b
Galecto BiotechNovember 03, 2014$444 m
F-star AlphaOctober 28, 2014$475 m
Show more

Bristol-Myers Squibb Revenue Breakdown

Embed Graph

Bristol-Myers Squibb revenue breakdown by business segment: 30.3% from Eliquis, 27.6% from Opdivo, 11.4% from Orencia, 8.1% from Sprycel, 5.7% from Yervoy, 6.4% from Other Brands and 10.6% from Other

Bristol-Myers Squibb revenue breakdown by geographic segment: 58.7% from United States, 24.0% from Europe, 15.3% from Rest of World and 2.0% from Other

Bristol-Myers Squibb Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Bristol-Myers Squibb Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Bristol-Myers Squibb Online and Social Media Presence

Embed Graph

Bristol-Myers Squibb Company Culture

  • Overall Culture

    A

    75/100

  • CEO Rating

    A+

    80/100

  • Compensation

    A+

    86/100

  • Diversity

    A

    77/100

Learn more on Comparably

Bristol-Myers Squibb News and Updates

Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: Reuters

Bristol Myers Squibb Co was sued for $6.4 billion for allegedly delaying approval for Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, acquired in 2019 for $80.3 billion in cash and stock.

$ 19.89 Billion growth expected in Antiviral Drugs Market during 2021-2025 | AbbVie Inc., Bristol-Myers Squibb Co., and F. Hoffmann-La Roche Ltd. Emerge as Major Vendors | Technavio

NEW YORK, May 31, 2021 /PRNewswire/ -- The antiviral drugs market is expected to grow by USD 19.89 billion during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the antiviral drugs market in optimistic, probable, and...

INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Bristol-Myers Squibb Company’s Directors and Officers for Breach of Fiduciary Duties – BMY

NEW YORK, May 20, 2021 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating certain directors and officers of Bristol-Myers Squibb Company (“Bristol-Myers”) (NYSE: BMY) for breaching their fiduciary …

Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb

Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY).

Worldwide Multiple Myeloma Treatment Industry to 2029 - Players Include Janssen Biotech, Bristol-Myers Squibb and Novartis Among Others

Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

Bristol Myers Squibb Licenses Patented Drug-Discovery Platform Technologies From Housey Pharma

Housey Pharma (http://www.housey.com) has entered into a license agreement of its core-enabling technologies for new-drug discovery with Bristol Myers Squibb. The announcement was made today by Gerard Housey, M.D., Ph.D., founder and CEO of Housey Pharma, based in Southfield, Mich.
Show more

Bristol-Myers Squibb Frequently Asked Questions

  • When was Bristol-Myers Squibb founded?

    Bristol-Myers Squibb was founded in 1887.

  • Who are Bristol-Myers Squibb key executives?

    Bristol-Myers Squibb's key executives are Giovanni Caforio, Jeff Staiger and Elizabeth Mily.

  • How many employees does Bristol-Myers Squibb have?

    Bristol-Myers Squibb has 30,000 employees.

  • What is Bristol-Myers Squibb revenue?

    Latest Bristol-Myers Squibb annual revenue is $42.5 b.

  • What is Bristol-Myers Squibb revenue per employee?

    Latest Bristol-Myers Squibb revenue per employee is $1.4 m.

  • Who are Bristol-Myers Squibb competitors?

    Competitors of Bristol-Myers Squibb include Daiichi Sankyo, Regeneron Pharmaceuticals and Gilead Sciences.

  • Where is Bristol-Myers Squibb headquarters?

    Bristol-Myers Squibb headquarters is located at 345 Park Avenue, 345 Park Ave, New York.

  • Where are Bristol-Myers Squibb offices?

    Bristol-Myers Squibb has offices in New York, Atlanta, Baltimore, Cambridge and in 50 other locations.

  • How many offices does Bristol-Myers Squibb have?

    Bristol-Myers Squibb has 56 offices.